Celixir company
Celixir is a developer of regenerative medicines created to change the lives of patients in need. The company's medicines consists of iMP cells, platelet lysate and PML cells to treat patients with ischaemic heart disease, injured tendons near the surface of the skin and mild to moderate heart failure respectively, enabling medical researchers to discover breakthrough medicines that aim to change the standard of medical care for patients.
Total Funding:
$2.6M
Headquarters:
Cardiff, Cardiff, United Kingdom
Funding Status:
M&A
Employee Number:
11-50
Investment Stage:
N/A
Last Funding Type:
Venture - Series Unknown
Number Of Exists:
Venture - Series Unknown
Technology:
P4 Medicine
Investor Type:
Company
Investors Number:
1
Founded Date:
Undisclosed
Industry:
Regenerative Medicine